

Index

Note: Page numbers of article titles are in **boldface** type.

A

- Alloimmunization, to transfused blood products, **467–473**
 - nonantibody-based immune responses, 469–471
 - risk factors for, 468–469
- American Rare Donor Program, 427
- American trypanosomiasis, 503
- Anemia
 - hemolytic
 - fetal blood group testing for, **431–442**
 - warm autoimmune, 424–425
 - preoperative correction of, 455, 457
- Anticoagulants, for blood salvage, 459
- Antigens
 - absence of, in universal donor cells, 398–399, 445
 - alloimmunization and, **467–473**
 - alteration of, for universal donor red blood cell products, 445
 - fetal, blood group testing for, **431–442**
 - molecular testing for, **419–429**
 - application of, 424–426
 - automation of, 426
 - costs of, 423–424
 - data management for, 426–427
 - polymorphism detection, 419–423
 - pig blood, 367–369
- Arboviruses, 504–505
- Automation, of red blood cell genotyping, 426

B

- Babesia*, 503–504
- Bead chip microarray analysis, for red blood cell genotyping, 422
- Bioreactors, for stem cell processes, 409–413
- Blood management, **453–465**
 - conservation strategies for
 - blood salvage in, 458–460
 - normovolemic hemodilution in, 457–458
 - point of care testing in, 460–462
 - preoperative anemia prevention in, 455, 457
 - program components in, 455–456
 - definition of, 454–455
 - impetus for, 453–454

- Blood Products Advisory Committee, red blood cell recovery methods of, 444
- Blood salvage, 458–460
- Blood substitutes, **381–389**
- biochemical engineering of, 382–384
 - biologic activity of, 384–386
 - potency of, 384–386
 - toxicity of, 386–387
 - versus cells derived from stem cells, 392
- Blood transfusion
- alloimmunization to, **467–473**
 - antigen testing for, **419–429**
 - avoidance or reduction of, **381–389, 453–465**
 - blood management and, **453–465**
 - blood supply for, 453–454
 - costs of, 453
 - European Blood Directive for, **489–497**
 - fetal blood grouping for, **431–442**
 - future status of, **405–417**
 - drivers of change for, 406–408
 - genetically engineered pigs and, 372–375
 - red blood cell enrichment for, 413–414
 - regulatory considerations in, 414–415
 - stem cells in. *See* Stem cell(s).
 - genetically engineered pigs for, **365–380**
 - history of, 405–406
 - need for, 406–407
 - pathogens in, 407, **499–509**
 - platelet storage lesion due to, **475–487**
 - products for, **443–452**
 - stem cell transformation for. *See* Stem cell(s).
 - substitutes for, **381–389**
- BLOODchip, for red blood cell genotyping, 421–422
- “Bloodless Center,” 454
- Bone marrow transplantation, after alloimmunization to blood products, 470
- Bovine spongiform encephalopathy, 501–502

C

- C antigens, fetal testing for, 437
- CD34 stem cells, red blood cells derived from, 408–411
- Cellular transfusion products, **443–452**
- platelets, 446–449
 - red blood cells, 444–446
- Chagas disease, 503
- Chikungunya virus, 504–505
- Chronic wasting disease, 505
- Contamination
- of blood products
 - alloimmunization and, 468–469
 - reduction of, 446–447
 - of salvaged blood, 460

Creutzfeldt-Jakob disease, variant, 501–502
Critical Path Initiative, 449
Culture, of stem cells, for red blood cell production, 391–403, 408–415

D

D antigen, fetal testing for, 431–437
Data management, for red blood cell genotyping, 425–426
DCLHb blood substitute, 383
Dengue virus, 504–505
Donors
 European Blood Directive policy for, 489–497
 screening of, for rare phenotypes, 425

E

E antigens, fetal testing for, 437
Erythrocytes. *See* Red blood cells.
Erythropoiesis-stimulating agents, for preoperative anemia, 455, 457
European Blood Directive, **489–497**
 development of, 490–492
 implementation of, 492–496
 testing requirements of, 493–495

F

Fetal blood group testing, **431–442**
 D phenotype, 432–437
 maternal plasma for, 431–432
 non-D groups, 437–438
 quality assurance for, 438
FiberCell Systems, bioreactors of, 411–412
Food and Drug Administration, blood product standards of, 443–449
Free radical formation, in blood substitutes, 386–387

G

Gal epitope, in pig blood, 367–368
Genotyping, of red blood cells, **419–429**
Geron Corp., stem cell studies of, 409

H

HbDex blood substitute, 383
HEA microarray analysis, for red blood cell genotyping, 422
HemoCue hemoglobin analyzer, 461–462
Hemodilution, acute normovolemic, 457–458
Hemoglobin, generation of, in red blood cells derived from stem cells, 396
Hemoglobin-based oxygen carriers
 biochemical engineering of, 382–384
 biologic activity of, 384–386

Hemoglobin-based (*continued*)
 potency of, 384–386
 toxicity of, 386–387
 versus cells derived from stem cells, 392
Hemolink, 383–384
Hemolytic anemia
 fetal blood group testing for, **431–442**
 warm autoimmune, 424–425
Hemopure, 383
HIV/AIDS, 500–501
Human immunodeficiency virus, 500–501
Human leukocyte antigens, alloimmunization and, 469–470
Humoral immunization, to transfused blood products, 468–469
Hypoxia-inducible factor, 385

I

Iron-deficiency anemia, preoperative correction of, 455, 457

K

Kell antigens, fetal testing for, 437

L

LifeBank USA, stem cell studies of, 409
Luminex system, for red blood cell genotyping, 422–423

M

Mad cow disease, 501–502
Major histocompatibility complex, alloimmunization and, 469–470
Mass spectrometry
 for fetal blood group testing, 434, 438
 for red blood cell genotyping, 422–423
Matrix-assisted laser desorption ionization time of flight, for D antigen, 434, 438
Melting-curve analysis, for red blood cell genotyping, 421
Methoxy-polyethylene glycol, for red cell camouflage, 375
Microarray analysis, for red blood cell genotyping, 421–422
Myelodysplastic syndrome, 398

N

NeuGc epitope, in pig blood, 367–368
Nitric oxide, blood substitute interactions with, 386–387

O

OpenArray, for red blood cell genotyping, 422–423
Oxidants, in blood substitutes, 386–387
Oxygen carriers, hemoglobin-based, **381–389**

Oxygen equilibrium curves, of blood substitutes, 384–386
Oxyhemoglobin, 383

P

Pathogens, **499–509**

- arboviruses, 504–505
- Babesia*, 503–504
- Chagas disease, 503
- HIV/AIDS, 500–501
- in platelet products, 447, 483
- in red blood cell products, 445–446
- problems with, 407
- retroviruses, 505–506
- transmissible spongiform encephalopathy, 501–502, 505
- variant Creutzfeldt-Jakob disease, 501–502
- West Nile virus, 502–503

Peroxidation, in blood substitutes, 387

Phenotype matching, 424–425

Pigs, genetically engineered, red blood cells from, **365–380**

- future of, 372–375
- history of, 366
- immunologic barriers and, 367–369
- polyethylene glycol-coated, 375
- primate studies of, 369–372
- similarity to human cells, 366–367

Platelet(s)

- degranulation of, tests for, 477
- morphology of, tests for, 477
- products containing
 - characterization of, 476–478
 - cold storage of, 446–447
 - evaluation of, 448–449
 - in vitro versus in vivo studies of, 478–481
 - novel technologies for, 483–484
 - pathogen reduction in, 447
 - production of, 476
 - shelf-life problems with, 475–476
 - stem cell-derived, 448
 - substitutes for, 447–448
 - transfusion outcome and, 482–482
 - viability tests for, 479–480

Platelet additive solutions, 483

Platelet storage lesion, **475–487**

Pluripotent stem cells, red blood cells derived from, 399

Point of care testing, in blood management, 460–462

Polymerase chain reaction

- for D antigen, 434
- for red blood cell genotyping, 420–422

Polymorphisms, of red blood cells, detection of, 419–423

Prions, 501–502

Pyrosequencing, for red blood cell genotyping, 421

Q

Quality assurance, for fetal blood group testing, 438

R

Red blood cells

antigens of. *See* Antigens.

from genetically engineered pigs, **365–380**

from stem cell transformation. *See* Stem cell(s).

genotyping of, **419–429**

application of, 424–426

automation of, 426

costs of, 423–424

data management for, 426–427

hemoglobin-based oxygen carriers prepared from, 382–384

products containing, 444–446

evaluation of, 444, 448–449

pathogen reduction in, 445–446

shelf life extension for, 445

storage of, 444–445

universal donor, 445

Regulations

for red blood cell transformation, 414–415

in European Blood Directive, **489–497**

Rejection, of products, 470

Reticulocytes, maturation and conservation of, 394, 396

Retroviruses, 505–506

RhD blood group, fetal testing for, 431–437

S

Salvage, of blood, 458–460

Sickle cell disease, 398

Simian foamy virus, 505–506

SNaPshot system, for red blood cell genotyping, 422

SNPstream system, for red blood cell genotyping, 422

Stem cell(s)

platelets derived from, 448

red blood cells derived from, **391–403**

candidates for, 398

differentiation of, 396, 413–414

enrichment strategies for, 413–414

for universal red blood cells, 398–399

future of, 400–402

industrial scale process for, 399–400

large-scale processes for, 409–413

lifespan study for, 397

marketing of, 400

maturation of, 394–396

need for, 391–393

- novel bioreactors for, 409–413
 - pluripotent, 399
 - potential of, 408–409
 - proliferation in, 393–394
 - quantitative aspect of, 397
 - regulatory considerations in, 414–415
 - simplification of procedure for, 396–397
- Stem Cell Systems, bioreactors of, 412–413
- Storage
- of platelet products, 446–447, **475–487**
 - of red blood cell products, 444–445
- Substitutes, for blood, **381–389**
- Swirl test, for platelet products, 478

T

- Transfusion, blood. See Blood transfusion.
- Transmissible spongiform encephalopathy, 501–502, 505
- Transplantation, after alloimmunization to blood products, 469–471
- Trypanosoma cruzi*, 503

U

- Universal donor red blood cells, 398–399, 445

W

- West Nile virus, 502–503

X

- Xenotransfusions, from genetically engineered pigs, **365–380**
- Xenotropic murine leukemia-like retrovirus, 506